NASDAQ:KIDS

OrthoPediatrics Stock Forecast, Price & News

$60.61
+0.35 (+0.58 %)
(As of 07/29/2021 01:00 PM ET)
Add
Compare
Today's Range
$60.04
$60.61
50-Day Range
$53.62
$67.51
52-Week Range
$38.01
$68.00
Volume96 shs
Average Volume154,514 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.68
30 days | 90 days | 365 days | Advanced Chart
Receive KIDS News and Ratings via Email

Sign-up to receive the latest news and ratings for OrthoPediatrics and its competitors with MarketBeat's FREE daily newsletter.


OrthoPediatrics logo

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.95 out of 5 stars

Medical Sector

330th out of 2,214 stocks

Surgical & Medical Instruments Industry

37th out of 185 stocks

Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











OrthoPediatrics (NASDAQ:KIDS) Frequently Asked Questions

Is OrthoPediatrics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OrthoPediatrics stock.
View analyst ratings for OrthoPediatrics
or view top-rated stocks.

What stocks does MarketBeat like better than OrthoPediatrics?

Wall Street analysts have given OrthoPediatrics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OrthoPediatrics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OrthoPediatrics' next earnings date?

OrthoPediatrics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for OrthoPediatrics
.

How can I listen to OrthoPediatrics' earnings call?

OrthoPediatrics will be holding an earnings conference call on Thursday, August 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "6982208".

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) announced its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.02. The company earned $21.46 million during the quarter, compared to the consensus estimate of $19.78 million. OrthoPediatrics had a negative net margin of 50.38% and a negative trailing twelve-month return on equity of 10.06%.
View OrthoPediatrics' earnings history
.

How has OrthoPediatrics' stock been impacted by COVID-19?

OrthoPediatrics' stock was trading at $39.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KIDS shares have increased by 52.5% and is now trading at $60.61.
View which stocks have been most impacted by COVID-19
.

What guidance has OrthoPediatrics issued on next quarter's earnings?

OrthoPediatrics issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $94 million-$98 million, compared to the consensus revenue estimate of $95 million.

What price target have analysts set for KIDS?

4 equities research analysts have issued 12-month price objectives for OrthoPediatrics' stock. Their forecasts range from $57.00 to $77.00. On average, they expect OrthoPediatrics' share price to reach $69.67 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts' price targets for OrthoPediatrics
or view top-rated stocks among Wall Street analysts.

Who are OrthoPediatrics' key executives?

OrthoPediatrics' management team includes the following people:
  • Mr. Mark C. Throdahl, Exec. Chairman (Age 70, Pay $560.28k)
  • Mr. David R. Bailey, Pres & CEO (Age 42, Pay $491.85k)
  • Mr. Fred L. Hite, CFO, Principal Financial & Accounting Officer, COO and Director (Age 53, Pay $491.85k)
  • Mr. Daniel J. Gerritzen, VP of Legal & HR, Gen. Counsel and Sec. (Age 51, Pay $399.9k)
  • Mr. Gregory A. Odle, Exec. VP of Commercialization (Age 51, Pay $411.56k)
  • Mr. Joel Batts, Sr. VP of Science & Technology
  • Dr. Peter F. Armstrong M.D., Chief Medical Officer & Chair of Surgeon Advisory Board (Age 74)
  • Mr. Joe Hauser, Sr. VP & GM of Trauma & Deformity Correction
  • Mr. Mark Karshner, Sr. VP of International Sales

What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?

15 employees have rated OrthoPediatrics CEO Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among OrthoPediatrics' employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of OrthoPediatrics' key competitors?

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), The Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

When did OrthoPediatrics IPO?

(KIDS) raised $52 million in an initial public offering (IPO) on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel acted as the underwriters for the IPO and William Blair and BTIG were co-managers.

What is OrthoPediatrics' stock symbol?

OrthoPediatrics trades on the NASDAQ under the ticker symbol "KIDS."

How do I buy shares of OrthoPediatrics?

Shares of KIDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrthoPediatrics' stock price today?

One share of KIDS stock can currently be purchased for approximately $60.61.

How much money does OrthoPediatrics make?

OrthoPediatrics has a market capitalization of $1.19 billion and generates $71.08 million in revenue each year. The company earns $-32,940,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does OrthoPediatrics have?

OrthoPediatrics employs 116 workers across the globe.

What is OrthoPediatrics' official website?

The official website for OrthoPediatrics is www.orthopediatrics.com.

Where are OrthoPediatrics' headquarters?

OrthoPediatrics is headquartered at 2850 Frontier Drive, Warsaw IN, 46582.

How can I contact OrthoPediatrics?

OrthoPediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company can be reached via phone at 574-268-6379 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.